Redeye: Rx pipeline for free in Moberg Pharma

Following the Q3 2017 report, we have adjusted our forecasts of Moberg Pharma slightly, which negatively impact the base case fair value. At current share price levels (SEK 28), we however believe the market has taken a too pessimistic approach to the pipeline assets, while overrating the risk of additional financing of the MOB-015 trials. Read more in the Research Update by Klas Palin: https://goo.gl/D3okFp

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/